What Bionsight does

Bionsight is a South Korea-based drug discovery company, founded in 2019 and headquartered in Chuncheon with an additional office in Seoul, that combines proprietary chemoproteomics methodologies with artificial intelligence to accelerate therapeutic target identification and validation. Its core technology stack centers on the Javelin platform, which pairs a novel "massive trypsinization" sample-preparation method with AI-based quantification to deliver proteome-wide peptide- and domain-level protein-ligand interaction maps, including dose-responses, on a 4-6 week timeline. Supporting AI capabilities include Glance for bio-object relationship analysis, Skeleton for 3D structure-based deep learning molecular optimization, and SynapSpec, a DIA mass spectrometry analysis solution with deep learning-optimized workflows; a DI-PELSA thermal shift assay and an internal drug pipeline (BIMM-1, 6, 8, 9, 10 spanning autoimmune, anti-cancer, and metabolic disease) round out the portfolio.

The company monetizes through a three-pronged model: an enterprise target profiling service sold via direct field sales with a consultation-first approach to pharmaceutical and biotech clients, platform technology licensing of its AI and proteomics tools, and internal drug candidate development. Its GTM is sales-led and event-driven, anchored by participation in major proteomics and life sciences conferences (HUPO, ASMS, BIO USA), peer-reviewed publication output, and selection for high-credibility programs including the Merck Research Grants (finalist 2022), Takeda's COCKPI-T funding program (2023), and South Korea's Scale-up TIPS (2024). Customer segments are horizontally distributed across pharmaceutical companies and biotech firms, with no named customer logos publicly disclosed.

Bionsight has raised approximately 55 billion KRW (~$41M USD) in Series A funding (August 2023) from SV Investment, DSC Investment, and Schmidt, supplemented by government Scale-up TIPS grants and prior pre-seed capital, and operates with a 11-50 person team. The company remains privately held with no disclosed revenue, and is positioning itself as a differentiated chemoproteomics-plus-AI alternative to conventional target deconvolution and validation workflows in drug discovery.

Name

Bionsight

Legal name

Bionsight, Inc.

Website

https://bionsight.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Bionsight is a South Korea-based drug discovery company combining proprietary chemoproteomics with AI to deliver proteome-wide target identification and validation services to pharmaceutical and biotech clients on a 4-6 week timeline.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826), Pharmaceutical Preparations (2834)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Proteomics & Biomarker Analytical Testing (HLAGADAG), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• AI drug discovery
• Chemoproteomics platform
• Target identification
• Mass spectrometry analysis
• Proteomics services

Headquarters

HQ city

Chuncheon

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Target Profiling Service: End-to-end target profiling service offering AI-powered protein target identification from hypothesis to validation in weeks. Includes target discovery, interaction mapping, data analytics, target validation, safety profiling, and expert support.
2. Platform Technology Licensing: Licensing of AI platform technologies (Javelin, Glance, Skeleton) to pharmaceutical companies and biotech firms for drug discovery applications.
3. Drug Pipeline Development: Internal drug candidate development across autoimmune disease, anti-cancer, and metabolic disease therapeutic areas. Programs include BIMM-1, BIMM-6, BIMM-8, BIMM-9, and BIMM-10 in various stages from discovery to preclinical.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Bionsight develops AI-powered chemoproteomics platforms for drug discovery, combining mass spectrometry with machine learning to deliver proteome-wide protein target profiling and validation. Its core offerings include the Javelin chemoproteomics platform, SynapSpec DIA mass spectrometry analysis, and end-to-end Target Profiling Services that identify therapeutic targets, map protein-ligand interactions, and profile off-target effects within 4-6 weeks, replacing multi-year traditional discovery workflows.

Product overview

Bionsight offers an integrated AI-powered chemoproteomics platform for drug discovery consisting of three core products: Javelin (AI-assisted chemoproteomics platform for proteome-wide target profiling), SynapSpec (advanced DIA mass spectrometry analysis with deep learning optimization), and a Drug Pipeline (therapeutic candidates in autoimmune, anti-cancer, and metabolic disease). The platform is complemented by a Target Profiling Service offering end-to-end外包服务 and the DI-PELSA assay methodology for thermal shift analysis. The company also developed supporting AI technologies including Glance (bio-object relationship analysis) and Skeleton (3D structure-based deep learning for molecular optimization).

Differentiator

Problem solved

Functional benefit

Brands

• Javelin: AI-Assisted Chemoproteomics Platform for protein target exploration, providing proteome-wide peptide/domain-level interaction maps with drug dose-responses in 4-6 weeks.
• SynapSpec
• DI-PELSA

Products and services

• Javelin AI-Assisted Chemoproteomics Platform that delivers proteome-wide peptide/domain-level interaction maps with drug dose-responses in 4-6 weeks. Provides on-target confirmation, binding-site clues at peptide/domain resolution, and off-target lists for go/no-go decisions. Modality-agnostic (small molecules, degraders, ADCs, biologics) and matrix-flexible (cells, organoids, tissues). Designed for pharmaceutical and biotech discovery teams.
• SynapSpec Advanced DIA (Data-Independent Acquisition) Mass Spectrometry Analysis Solution for proteomics, featuring deep learning-optimized workflows, real-time data processing and analysis, automated mass spectrometry optimization, and cross-platform compatibility. Used by pharma and biotech researchers for proteomics analysis supporting drug discovery.
• Drug Pipeline Therapeutic Development Portfolio encompassing drug candidates across autoimmune disease (BIMM-1, BIMM-8, BIMM-9), anti-cancer (BIMM-10), and metabolic disease (BIMM-6). Programs span discovery to preclinical stages and are pursued for licensing and partnering with global pharmaceutical companies.
• Target Profiling Service End-to-end target profiling service powered by AI and chemoproteomics, offering target discovery, interaction mapping, data analytics, target validation, safety profiling, and expert scientific support. Delivers results in approximately 4 weeks. Targets pharmaceutical companies and biotech firms needing outsourced, comprehensive proteome-wide profiling.
• DI-PELSA Data-Independent-Precipitation-based Enzyme-Linked Thermal Shift Assay platform used for target profiling of drug candidates in cellular systems. Demonstrated in case studies including MEK1/2 inhibitor profiling in A549 lung cancer cells. Underpins Bionsight's Target Profiling Service and chemoproteomics platform.

Quantifiable outcome

• 4-6 weeks delivery vs traditional multi-year target identification timelines
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• Ministry of SMEs and Startups (South Korea)coreOthers · 5 September 2024Selected for Scale-up TIPS program receiving up to 11.4 billion KRW over 3 years for Javelin platform development. Also selected for Post-TIPS 2nd program with 300 million KRW government support. Funds designated for platform technology development, professional hiring, and facilities expansion.
• Takeda Pharmaceutical Company (COCKPI-T Program)coreStrategic or Co-development Partner · 8 February 2023Selected for Takeda's COCKPI-T Funding Program - a global initiative to accelerate drug discovery innovation. Provides one year of research support, access to Takeda's research network, joint project execution opportunities, and funding support. Marks an important step in strengthening collaborative R&D capabilities.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Schrödinger: Schrödinger operates a physics-based computational platform for molecular design and predicts drug properties using AI/ML, offering comparable target identification and lead optimization services to pharma with similar service-plus-pipeline business model.
• Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover and develop drugs across multiple therapeutic areas, competing with Bionsight in the AI-enabled target identification and pipeline development space.
• Exscientia: Exscientia is an AI-driven precision medicine company with a platform that automates drug design and patient stratification, directly comparable to Bionsight's AI-platform-plus-pipeline approach serving pharma clients.
• Insitro: Insitro applies machine learning to disease biology, combining induced pluripotent stem cell models with ML for target discovery and drug development, paralleling Bionsight's AI-biology integration for therapeutic development.
• Standigm: Standigm is a South Korea-based AI drug discovery company that builds proprietary pipelines and offers drug discovery services using AI workflows, the closest regional and stage-comparable peer to Bionsight.
• BenevolentAI: BenevolentAI uses AI to mine biomedical knowledge for target discovery and drug development, offering comparable AI-driven target identification capabilities with a pipeline-plus-services model to pharma.

Emerging players

• Atomwise: Atomwise leverages structure-based AI for small molecule drug discovery, sharing Bionsight's AI-driven target-and-lead optimization focus but with greater emphasis on virtual screening rather than chemoproteomics.
• Seer: Seer provides a proteomics platform (Proteograph) using nanoparticle-enabled mass spectrometry for deep proteomic profiling, comparable to Bionsight's mass spec-driven Javelin target profiling workflow.
• Owkin: Owkin applies AI to multimodal patient data for drug discovery and diagnostics, an adjacent peer sharing AI-biology integration but focused more on patient-derived data than wet-lab chemoproteomics.

Broad incumbents

• Bruker Corporation: Bruker is a major mass spectrometry and proteomics instrumentation company whose timsTOF and DIA platforms underpin similar proteomics workflows to Bionsight's SynapSpec, representing a potential partner or competitor in proteomics-grade analytics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/posts/bionsight_hupo2024-chemoproteomics-proteomics-activity-7254405809961328642-d6XN
• Xx.com/bionsight

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionsight